KV1.3 binding immunoglobulins

US11149086B2 · kind B2 · utility

Assignee

• Ablynx N.V. · BE

Inventors

• Diane Van Hoorick · Laarne, BE
• Erik Depla · Laarne, BE
• Frank Kamiel Delphina Verdonck · Sint-Gillis-Waas, BE
• Veerle Delanote · Sint-Kruis, BE
• Daniel Janssen · Puurs, BE
• Francis Descamps · Roeselare, BE
• Mark Edward Labadia · Ridgefield, US
• Ann Mikhail · Ridgefield, US
• Alisa K. Waterman · Weston, US

Key dates

• Filing date: Jun 18, 2015
• Grant date: Oct 19, 2021
• Expiry date: Mar 20, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.